Home

Laurent Fischer

CIK 1379344 · CEO, PRESIDENT AND DIRECTOR · last filed 2026-06-17

Laurent Fischer is a CEO, PRESIDENT AND DIRECTOR who has filed 49 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for MIRM, was dated Jun 17, 2026. Across all open-market trades the lifetime net is +$899.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.06M

Companies

6

Total Filings

49

Lifetime Open-Market Net

$899.9K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MIRM Director 10,727 $99.16 $1.06M $69.0K 10 2026-06-17
ATAI Director — $7.26 — $0 3 2026-06-08
Adverum Biotechnologies, Inc. (ADVM) Delisted CEO, PRESIDENT AND DIRECTOR 522,666 $4.36 $2.28M $830.9K 21 2025-12-10
CTI BIOPHARMA CORP (CTIC) Delisted Director — $9.09 — $0 8 2023-06-26
Tobira Therapeutics, Inc. (TBRA) Delisted Chief Executive Officer — — — $0 3 2016-01-14
PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Director — — — $0 3 2008-06-30

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 MIRM Grant (A) — $0 EDGAR
2026-06-08 ATAI Grant (A) — $0 EDGAR
2026-06-02 MIRM Exer (M) +3,977 $0 EDGAR
2025-12-10 Adverum Biotechnologies, Inc. (ADVM) Delisted Mixed −249,179 $630.0K EDGAR
2025-12-08 Adverum Biotechnologies, Inc. (ADVM) Delisted Buy (P) +128,699 $553.9K EDGAR
2025-06-27 ATAI Grant (A) — $0 EDGAR
2025-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Mixed — $0 EDGAR
2025-06-02 MIRM Grant (A) — $0 EDGAR
2025-05-16 Adverum Biotechnologies, Inc. (ADVM) Delisted Sell (S) −9,126 -$18.3K EDGAR
2025-02-27 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) +25,000 $0 EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.